OC
TCRT icon

Oakworth Capital’s Alaunos Therapeutics TCRT Stock Holding History

Oakworth Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7
Closed -$4K – 581
2019
Q3 		$4K Hold
7
– – ﹤0.01% 498
2019
Q2 		$6K Hold
7
– – ﹤0.01% 525
2019
Q1 		$4K Hold
7
– – ﹤0.01% 516
2018
Q4 		$2K Hold
7
– – ﹤0.01% 549
2018
Q3 		$3K Hold
7
– – ﹤0.01% 550
2018
Q2 		$3K Hold
7
– – ﹤0.01% 573
2018
Q1 		$4K Buy
+7
New +$4.36K ﹤0.01% 531

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oakworth Capital's TCRT Position: Q4 2019 in Review

Oakworth Capital sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 7 shares — an estimated $4K sold.

Oakworth Capital first reported a position in TCRT in Q1 2018 and held it in 7 quarters. The position peaked at $6K in Q2 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

  • Oakworth Capital reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Oakworth Capital sold 7 Alaunos Therapeutics shares in Q4 2019, an estimated $4K.
  • Oakworth Capital first reported a position in Alaunos Therapeutics in Q1 2018 and held it in 7 quarters.
  • Oakworth Capital's Alaunos Therapeutics position peaked at $6K in Q2 2019.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on Oakworth Capital's 13F filing for Q4 2019, filed 31 Jan 2020.